Interferon tau mutants and methods for making them
CA 2382425 A1 · Owner: Clark, Christina Dancz · Inventors: Clark, Christina Dancz; Shorts, Lynnette H.; Pontzer, Carol H.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to the field of animal and human health and , more particularly to pharmacological uses of analogs or mutants of interferontau (IFN-.tau.) that differ from native IFN-.tau. because of substitutions of amino acids near the amino terminus of the IFN-.tau. molecule that impart improved biological activity. The IFN-.tau. mutants described in this disclosure have low toxicity, retain the same or slightly reduced antiviral activity compared with highly effective IFN-alpha and have enhanced , antiproliferative activity compared to native IFN-tau making them useful in , treating viral infections cancer, and immune system diseases including autoimmune diseases. …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 22, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 22, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 22, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.